Matches in SemOpenAlex for { <https://semopenalex.org/work/W1805762008> ?p ?o ?g. }
- W1805762008 endingPage "283" @default.
- W1805762008 startingPage "277" @default.
- W1805762008 abstract "Human recombinant granulocyte colony–stimulating factor (G-CSF), filgrastim (Neupogen; Amgen, Thousand Oaks, CA, USA), has been widely used for the mobilization of CD34+ hematopoietic stem cells (HSC) from healthy donors. The experience with biosimilar G-CSF agents in this area is limited. We performed a prospective study assessing Tevagrastim (biosimilar filgrastim, XMO2; Teva, Israel) for mobilization of CD34+ peripheral blood HSC in HLA-matched healthy sibling donors for transplantation in 24 patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS) (NCT01542944). Results were compared to a historical control group of sibling donors who received filgrastim for stem cell mobilization for allogeneic stem cell transplantations in patients with AML and MDS. The healthy donors received Tevagrastim or filgrastim in a dose of 10 μg/kg body weight (BW) subcutaneously for 4 days. The target yields of CD34+ cells was 5 × 106 CD34+ cells/kg BW of the recipient. A median 10.2 × 106 (range, 2.52 to 35.4) and 9.35 × 106 (range, 3.7 to 30.6) CD34+ cells per kg BW were collected in the Tevagrastim and filgrastim groups, respectively. All patients promptly engrafted with a median day of absolute neutrophil count (ANC) of >.5 × 109/L and >1 × 109/L of 13 days (range, 10 to 21) and 13.5 days (range, 10 to 22), respectively in the Tevagrastim group and 12 days (range, 10 to 18) and 13 days (range, 10 to 18) in the filgrastim group, respectively. Platelets reached counts of >20 × 109/L and >50 × 109/L within a median of 14 days (range, 11 to 33) and 17 days (range, 12 to 33) in the Tevagrastim group and 13 (range, 10 to 29) and 15 (range, 10 to 32) days in the filgrastim group, respectively. The donors developed only mild and transient side effects, which were not different between the Tevagrastim study group and the filgrastim historical control group. Similarly, the transplantation-related toxicities and outcomes did not differ between the patients who underwent transplantation with Tevagrastim-mobilized grafts and the filgrastim historical controls. In summary, we observed a similar yield of CD34+ stem cell mobilization in the Tevagrastim study group and the filgrastim historical control group with similar engraftment kinetic, hematopoietic reconstitution, and transplantation outcome. Tevagrastim administration was safe with minimal side effects and toxicity not different than historical controls. The lack of significant differences for all parameters of stem cell collection, engraftment, and safety with the biosimilar XMO2 Tevagrastim demonstrate the “similarity” of the biosimilar and recombinant human G-CSF in this indication." @default.
- W1805762008 created "2016-06-24" @default.
- W1805762008 creator A5003511896 @default.
- W1805762008 creator A5008843573 @default.
- W1805762008 creator A5012875195 @default.
- W1805762008 creator A5020301140 @default.
- W1805762008 creator A5045152818 @default.
- W1805762008 creator A5058925624 @default.
- W1805762008 creator A5081737366 @default.
- W1805762008 date "2016-02-01" @default.
- W1805762008 modified "2023-10-18" @default.
- W1805762008 title "Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes" @default.
- W1805762008 cites W1968659034 @default.
- W1805762008 cites W1969787209 @default.
- W1805762008 cites W1975226386 @default.
- W1805762008 cites W1977123599 @default.
- W1805762008 cites W1980769405 @default.
- W1805762008 cites W1981437109 @default.
- W1805762008 cites W1992090010 @default.
- W1805762008 cites W1996429338 @default.
- W1805762008 cites W2024982393 @default.
- W1805762008 cites W2026625631 @default.
- W1805762008 cites W2033144445 @default.
- W1805762008 cites W2042055313 @default.
- W1805762008 cites W2044931811 @default.
- W1805762008 cites W2057475999 @default.
- W1805762008 cites W2068722337 @default.
- W1805762008 cites W2071253163 @default.
- W1805762008 cites W2074425311 @default.
- W1805762008 cites W2099610092 @default.
- W1805762008 cites W2106429556 @default.
- W1805762008 cites W2119740605 @default.
- W1805762008 cites W2122468868 @default.
- W1805762008 cites W2162309072 @default.
- W1805762008 cites W2162703233 @default.
- W1805762008 cites W2171317601 @default.
- W1805762008 cites W2240289126 @default.
- W1805762008 cites W4246085869 @default.
- W1805762008 doi "https://doi.org/10.1016/j.bbmt.2015.08.033" @default.
- W1805762008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26343949" @default.
- W1805762008 hasPublicationYear "2016" @default.
- W1805762008 type Work @default.
- W1805762008 sameAs 1805762008 @default.
- W1805762008 citedByCount "12" @default.
- W1805762008 countsByYear W18057620082016 @default.
- W1805762008 countsByYear W18057620082017 @default.
- W1805762008 countsByYear W18057620082018 @default.
- W1805762008 countsByYear W18057620082019 @default.
- W1805762008 countsByYear W18057620082021 @default.
- W1805762008 countsByYear W18057620082022 @default.
- W1805762008 crossrefType "journal-article" @default.
- W1805762008 hasAuthorship W1805762008A5003511896 @default.
- W1805762008 hasAuthorship W1805762008A5008843573 @default.
- W1805762008 hasAuthorship W1805762008A5012875195 @default.
- W1805762008 hasAuthorship W1805762008A5020301140 @default.
- W1805762008 hasAuthorship W1805762008A5045152818 @default.
- W1805762008 hasAuthorship W1805762008A5058925624 @default.
- W1805762008 hasAuthorship W1805762008A5081737366 @default.
- W1805762008 hasBestOaLocation W18057620081 @default.
- W1805762008 hasConcept C10205521 @default.
- W1805762008 hasConcept C126322002 @default.
- W1805762008 hasConcept C143998085 @default.
- W1805762008 hasConcept C203014093 @default.
- W1805762008 hasConcept C2776694085 @default.
- W1805762008 hasConcept C2777408962 @default.
- W1805762008 hasConcept C2777767877 @default.
- W1805762008 hasConcept C2778461978 @default.
- W1805762008 hasConcept C2779171977 @default.
- W1805762008 hasConcept C2780007613 @default.
- W1805762008 hasConcept C2780817109 @default.
- W1805762008 hasConcept C28328180 @default.
- W1805762008 hasConcept C2911091166 @default.
- W1805762008 hasConcept C54355233 @default.
- W1805762008 hasConcept C59491497 @default.
- W1805762008 hasConcept C71924100 @default.
- W1805762008 hasConcept C86803240 @default.
- W1805762008 hasConcept C90924648 @default.
- W1805762008 hasConceptScore W1805762008C10205521 @default.
- W1805762008 hasConceptScore W1805762008C126322002 @default.
- W1805762008 hasConceptScore W1805762008C143998085 @default.
- W1805762008 hasConceptScore W1805762008C203014093 @default.
- W1805762008 hasConceptScore W1805762008C2776694085 @default.
- W1805762008 hasConceptScore W1805762008C2777408962 @default.
- W1805762008 hasConceptScore W1805762008C2777767877 @default.
- W1805762008 hasConceptScore W1805762008C2778461978 @default.
- W1805762008 hasConceptScore W1805762008C2779171977 @default.
- W1805762008 hasConceptScore W1805762008C2780007613 @default.
- W1805762008 hasConceptScore W1805762008C2780817109 @default.
- W1805762008 hasConceptScore W1805762008C28328180 @default.
- W1805762008 hasConceptScore W1805762008C2911091166 @default.
- W1805762008 hasConceptScore W1805762008C54355233 @default.
- W1805762008 hasConceptScore W1805762008C59491497 @default.
- W1805762008 hasConceptScore W1805762008C71924100 @default.
- W1805762008 hasConceptScore W1805762008C86803240 @default.
- W1805762008 hasConceptScore W1805762008C90924648 @default.
- W1805762008 hasIssue "2" @default.
- W1805762008 hasLocation W18057620081 @default.
- W1805762008 hasLocation W18057620082 @default.